Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The investigators will compare the reduction in Borg dyspnea score during the 3-min constant
rate shuttle walking test after 3 weeks of indacaterol 110 µg/Glycopyrronium 50 µg (Ultibro®)
versus Tiotropium 18 µg (Spiriva®) alone in patients with moderate to severe COPD.